Scarica l'app Stockscreener
12.94
6.50%
0.79
Pre-mercato:
12.51
-0.43
-3.32%
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Profit Recap: What are analysts price targets for Vor Biopharma IncQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Vor Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vor Biopharma Inc.(NasdaqGS: VOR) added to S&P Biotechnology Select Industry Index - marketscreener.com
If You Invested $1,000 in Vor Biopharma Inc. (VOR) - Stock Titan
Short Covering: Should value investors consider Vor Biopharma Inc2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus
Wells Fargo initiates coverage of Vor Biopharma (VOR) with overweight recommendation - MSN
Wells Fargo Initiates Coverage on VOR with Overweight Rating | V - GuruFocus
Vor Biopharma (NASDAQ:VOR) Now Covered by Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Vor Biopharma at Overweight With $30 Price Target - marketscreener.com
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target - MSN
RA Capital raises Vor Biopharma (VOR) reported beneficial stake to 19.9% - Stock Titan
Vor Biopharma Inc expected to post a loss of $1.64 a shareEarnings Preview - TradingView
Fcpm Iii Services B.V. Takes $18.50 Million Position in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
About Us | Oil & Gas JournalVor Biopharma Inc.Common Stock (Nasdaq:VOR) Stock Quote - FinancialContent
Guidance Update: Can Vor Biopharma Inc keep up with sector leadersTrade Exit Report & Reliable Breakout Forecasts - baoquankhu1.vn
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 24.5% in February - MarketBeat
VOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VOR: Telitacicept advances in late-stage trials for MG and Sjögren's, targeting major autoimmune markets - TradingView
VOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference - GlobeNewswire
Pharma News: What are the analyst revisions for Vor Biopharma IncIs DMAC stock a good investment in YEARJuly 2025 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Vor Biopharma Inc (VOR) Stock Price, Quote, News & History - Benzinga
[SCHEDULE 13G/A] Vor Biopharma Inc. Amended Passive Investment Disclosure - Stock Titan
Vor Bio Names Khan as Chief Medical Affairs Officer - Intellectia AI
Vor Bio Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4) - Intellectia AI
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
VOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VOR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Qiming funds disclose Vor Biopharma (VOR) common-stock holdings below 5% - Stock Titan
Vor Biopharma (NASDAQ:VOR) Stock Price Down 4%What's Next? - MarketBeat
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Exit Recap: Can Vor Biopharma Inc. keep up with sector leadersJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
VOR Stock Unaffected by Selling Stockholders' Actions - GuruFocus
Is Vor Biopharma Inc. gaining market shareDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug EndMonth: What is the PEG ratio of Vor Biopharma IncGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Vor Biopharma Inc. (VOR) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
VOR: Telitacicept drives a global autoimmune strategy, backed by strong data, funding, and expert leadership - TradingView — Track All Markets
Form 8K Vor Biopharma Inc For: 12 January By Investing.com - Investing.com
Quarterly Risk: How Vor Biopharma Inc stock valuations compare to rivals2025 Retail Activity & Weekly Top Performers Watchlists - Bộ Nội Vụ
Vor Biopharma Inc. Common Stock (VOR) Stock Price Today & Analysis - Gotrade
Citigroup Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation - Nasdaq
Vor Biopharma (VOR) Receives New 'Buy' Rating From Citigroup | V - GuruFocus
Citigroup Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Citi Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
How Vor Biopharma Inc. stock responds to policy changes2025 EndofYear Setup & Growth Focused Investment Plans - ulpravda.ru
Will Vor Biopharma Inc. stock return to pre crisis levelsMarket Sentiment Report & Community Consensus Picks - ulpravda.ru
How Vor Biopharma Inc. stock valuations compare to rivals2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Why Vor Biopharma Inc. stock remains a top recommendationTrade Volume Report & Stock Timing and Entry Methods - ulpravda.ru
Guidance Update: How Vor Biopharma Inc. stock responds to policy changes2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):